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are complementary technologies. METHODS: We extracted
data for 5016 PCI patients with DES or non-DES, admitted
between April 24 and June 30, 2003 from the Solucient, LLC
ACTracker database—a proprietary database with detailed drug
information. Patients were identiﬁed as having received a
GPIIb/IIIa inhibitor if they received any of the following drugs:
abciximab, tiroﬁban, or eptiﬁbatide. The likelihood of a patient
with a DES receiving a GPIIb/IIIa inhibitor was modeled using
a logistic regression equation, adjusting for hospital and demo-
graphic characteristics, as well as whether the patient had an
acute myocardial infarction (AMI). RESULTS: Patients under-
going PCI with a DES were less likely than those undergoing PCI
with a non-DES to receive a GPIIb/IIIa inhibitor. However, the
results were not statistically signiﬁcant. (OR = 0.917, 95% CI
0.793, 1.061). CONCLUSIONS: Data from the time period just
after approval of drug-eluting stents does not show any statisti-
cally signiﬁcant difference between use of GPIIb/IIIa inhibitors
among PCI patients receiving DES and non-DES. However, the
lower use of GPIIb/IIIa inhibitors among DES patients in our
study may prove to be signiﬁcant once data from additional PCI
patients becomes available.
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CLINICAL PHARMACIST INVOLVMENT IN COMMUNITY
ANTICOAGULATION CONTROL
Guy-Alfandary S, Raz M,Timkin N,Triki N, Katz M
Maccabi Healthcare Services, Azur, Israel
Many patients are chronically treated with oral anticoagulants
to prevent thromboembolic events. These medications are life
saving but have a narrow therapeutic window, which can expose
these patients to life threatening events if the International 
Normalized Ratio (INR) is not kept within the therapeutic
window. High potential of drug-drug and drug-food interactions
adds to the complexity of achieving good anticoagulation
control, and knowledge of these interactions can assist in making
better therapeutic decisions. OBJECTIVE: To evaluate the
impact of clinical pharmacist intervention on anticoagulation
control in chronic patients. METHODS: Thirty-seven chronic
patients with uncontrolled anticoagulation were randomly iden-
tiﬁed from the data systems of Maccabi Health care Services. The
clinical pharmacist intervention consisted of meeting the family
practitioners in order to go over patient clinical charts, and
sending written recommendations regarding anticoagulation
control. Some of the patients were also invited to a personal
meeting with the clinical pharmacist for pharmaceutical guid-
ance, and were closely followed throughout the process.
Outcome analysis was based on comparison of the last two INR
results before and after the clinical pharmacist intervention,
according to target INRs, matching the speciﬁc indication for
anticoagulant therapy. RESULTS: Following the clinical phar-
macist intervention we observed a two-fold increase in the
number of patients with anticoagulation control: a 2.5 fold
increase in the number of patients with anticoagulation control
in the optimal range (INR between 2–3 for most of the indica-
tions and 3–4 for mechanical valve replacement), and a 1.8 fold
increase in the number of patients with anticoagulation control
in the tolerable range (INR between 1.8–4 for most of the 
indications and 2–4.25 for mechanical valve replacement). These
differences were statistically signiﬁcant (p = 0.018). CONCLU-
SION: These ﬁndings indicate that chronic patient’s anticoagu-
lation control strongly beneﬁts from clinical pharmacist
intervention. Further study is required to control for sponta-
neous patient improvement.
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DISORDERS OF LIPOID METABOLISM: LIKELIHOOD OF
PRESCRIPTION THERAPY
Hess GP, Lipskiy N
Surveillance Data, Plymouth Meeting, PA, USA
OBJECTIVES: Individuals with hyperlipidemia are at risk for
CHD, hypertension and diabetes. This study examined the like-
lihood of receiving prescription therapy based on patient diag-
noses, demographics and other factors. METHODS: The study
design was retrospective covering January 2000–December
2002. It encompassed 15,000 electronic medical records from
primary care practices in eight States. Patients with lipoid disor-
ders were identiﬁed by ICD-9 diagnoses. Treatment patterns and
laboratory data were evaluated vs. NCEP ATP III Guidelines.
RESULTS: On average, 23.4% of patients eligible for treatment
according to the Guidelines were prescribed cholesterol lower-
ing drugs. Of those, 40.5% of patients (95% CI 39.6%–41.3%)
had prescription therapy without a hyperlipidemia diagnosis. In
each of these cases, one or more co-morbid diagnoses for CHD
risk were present. The likelihood of treatment for patients <45
years was 1.37 times lower (p < 0.001) than older patients in the
“ofﬁcial” risk age for CHD (55–64 years). The probability of
treatment for men was higher than for women (OR 1.11 p <
0.01). There was no signiﬁcant difference in treatment frequency
for Caucasians vs. blacks. The likelihood of treatment for
patients with documented hyperlipidemia was 3.86 times higher
than for those without a diagnosis (p < 0.0001). The likelihood
of treatment for patients with CHD was 1.6 times higher
(1.59–1.89) than for patients without. CONCLUSIONS: In
patients diagnosed with lipoid disorders and at risk for CHD,
the use of cholesterol lowering medication appears to be rela-
tively low compared to that recommended by the NCEP ATP III
Guidelines. In those patients who are prescribed cholesterol 
lowering medication without documented hyperlipidemia, the
presence of CHD risk factors appear to be a major considera-
tion. Possible reasons for a relatively low level of prescribing
include undocumented treatment by life style changes, lack of
awareness of NCEP guidelines by physicians, economic 
constraints, and/or other factors.
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LOWER INCIDENCE OF MICROVASCULAR EVENTS
ASSOCIATED WITH PIOGLITAZONE MONOTHERAPY THAN
INSULIN MONOTHERAPY IN PATIENTS WITH TYPE 2
DIABETES: A RETROSPECTIVE PROPENSITY SCORE
MATCHED COHORT ANALYSIS
Rajagopalan R1, Xu Y1, Rosenson R2
1Takeda Pharmaceuticals North America Inc, Lincolnshire, IL, USA;
2Northwestern University, Feinberg School of Medicine, Chicago, IL,
USA
OBJECTIVE: To examine the microvascular risk associated with
use of pioglitazone monotherapy versus insulin monotherapy 
in type 2 diabetes patients by retrospective analysis of the 
GE Medical Systems (GEMS) clinical database. METHODS:
Patients ≥18 years of age with a diagnosis of type 2 diabetes mel-
litus were included if on active treatment after 1999, and if no
microvascular events (one or more of neuropathy, nephropathy,
or retinopathy) were present at baseline. Only patients who were
initiated with pioglitazone or insulin as monotherapy were
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included. The index date was chosen such that each patient had
at least 6 month’s treatment with either of the products—before
and at least 6 months after that date. Patients receiving other
oral anti-diabetic drugs were excluded. To compensate for lack
of double-blind randomization and to reduce selection bias,
patients in the pioglitazone group were matched 1 :1 with the
insulin group based on propensity score calculated using demo-
graphic characteristics, co-morbidities, medical therapies, dura-
tion of diabetes, and duration of treatment. The odds ratio for
the microvascular event in the follow-up period was determined
using logistic regression with treatment as a factor and signiﬁ-
cant (p < 0.1) baseline characteristics as covariates in the model.
RESULTS: A total of 453 patients in the pioglitazone group were
matched to 453 patients in the insulin group. The crude event
rate in the pioglitazone group was 3.09% compared with 
9.49% in the insulin group (p < 0.001) and the odds ratio was
0.304 for pioglitazone (95% CI = 0.164, 0.564; p < 0.001). The
signiﬁcant risk reduction projected for the pioglitazone group
could not be completely explained by baseline laboratory 
measurements of lipids, serum creatinine, blood pressures, or
duration of diabetes. CONCLUSION: In this retrospective,
propensity-matched analysis in patients with type-2 diabetes, the
pioglitazone-treated group was associated with a signiﬁcantly
lower incidence of microvascular events than the insulin-treated
group.
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COMPARISON OF PIOGLITAZONE WITH OTHER
ANTIDIABETIC DRUGS FOR ASSOCIATED INCIDENCE OF
LIVER FAILURE: NO EVIDENCE OF INCREASED LIVER
FAILURE WITH PIOGLITAZONE 
Rajagopalan R, Iyer S, Perez A
Takeda Pharmaceuticals North America Inc, Lincolnshire, IL, USA
OBJECTIVE: To assess the incidence of liver failure in associa-
tion with anti-diabetic treatment using pioglitazone versus other
oral anti-diabetic medications. METHODS: The study was a ret-
rospective analysis of claims data from the PharMetrics Patient-
Centric Database that had over 1.12 million enrollees with type
2 diabetes. All patients ≥18 years of age with type 2 diabetes
who had initiated treatment with either a thiazolidinedione
(pioglitazone and rosiglitazone), sulfonylurea, or metformin
were identiﬁed and matched on the basis of propensity scores,
which served as a proxy for severity of disease. The primary
measure of interest was the incidence of liver failure or hepati-
tis post-index date. In addition to unadjusted comparisons, Cox
proportional hazards models were employed to estimate the risk
of developing liver failure or hepatitis. RESULTS: There was no
signiﬁcant difference in the 1-year and 2-year incidence rates of
liver failure or hepatitis (primary and secondary diagnosis)
between the pioglitazone monotherapy group and respective
comparator groups (pairs matched with rosiglitazone, n = 1847
(p > 0.808); with sulfonylurea, n = 1474 (p > 0.219); and with
metformin, n = 1137 (p > 0.284)). Cox proportional hazards
models controlling for age, pre-index total health care costs,
charlson comorbidity index, procedures and a hospitalization or
ER visit for pre-index hyperglycemia echoed these results.
Further, no primary or secondary diagnosis of liver failure was
reported in the pioglitazone group during the follow-up period.
CONCLUSION: Results of retrospective data analysis using the
PharMetrics cohort of patients with type 2 diabetes demonstrate
that there is no evidence of increased risk of liver failure or
hepatitis for patients initiating therapy on pioglitazone compared
to other oral anti-diabetic agents. Pioglitazone therapy was not
associated with an increased risk of liver failure at 2 years 
relative to other oral anti-diabetic therapies.
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EVALUATION OF PHARMACIST INTERVENTIONS IN
DIABETIC PATIENTS FROM RURAL COMMUNITY HEALTH
CENTERS
Pinto S, Segal R,Winterstein AG,Annis L, Robinson D,Yates D,
Pederson L,Willis M
University of Florida, Gainesville, FL, USA
OBJECTIVES: The project focuses on improving the drug use
process in the management of patients with chronic diseases,
especially diabetes. This HRSA funded program includes educa-
tion and training of pharmacists in ﬁve community health centers
about speciﬁc disease state therapies, monitoring, and manage-
ment. The study hypotheses are: 1) patients exposed to the inter-
vention will have improved medical and patient outcomes based
on changes in HbA1c, diabetes symptoms, LDL, blood pressure,
and health related quality-of-life, and 2) process measures con-
sistent with best practices will improve for patients exposed to
the intervention. METHODS: The project uses a prospective
design to determine whether exposure to the intervention over
two years leads to improved outcomes and processes of care.
Patients are the unit-of analysis and serve as their own controls.
Subjects include adults with Type 2 Diabetes Mellitus and
HbA1c >8mg/dL within a 3-month period of enrollment. Sub-
jects meeting the inclusion criteria are consecutively drawn from
a subset of clinic patients. Medical outcome data are collected
from medical and laboratory records, pharmacy records and
patient self-report. Study measures include clinical indicators,
quality-of-life, satisfaction and HEDIS diabetes-related process
measures. Outcomes and process data is collected at baseline and
every six months. RESULTS: Of the 142 patients enrolled in the
study, 137 are at the 6-month level and 104 are at the 12-month
level. The means at baseline for HbA1c, lipids and blood pres-
sure were 9.45, 122.54 (LDL), 136.63 (systolic) and 80.70 (dias-
tolic) while the six-month means were 8.53, 110.74, 135.16,
79.59 respectively. Wilcoxon Sign-Ranked test indicated signiﬁ-
cant differences in HbA1c and LDL mean values (p <= 0.000 &
p <= 0.10 respectively). However, the differences were non-
signiﬁcant for blood pressure values. CONCLUSIONS: The
baseline and 6 month values of these clinical markers indicate
an improvement in diabetes health outcomes for the patients
included in this initiative. Early ﬁndings support a positive
impact of pharmaceutical care on diabetes outcomes.
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PARTICIPATION IN HOME-BASED A1C TESTING IN
CAREPATTERNS® PROGRAM FOR DIABETES 
Berger J, Low D, Hu L, Stine N
Caremark, Northbrook, IL, USA
OBJECTIVES: Even though guidelines suggest glycosylated
hemoglobin A1c (HbA1c) testing at least twice a year for dia-
betics and despite the correlation between long term glycemic
control and reductions in overall health care costs and service
utilization, studies have estimated that only 75% of diabetes
patients receive annual HbA1c screening. The purpose of this
study was to examine the relationship between participation in
a free HbA1c home-testing program and several individual-
speciﬁc variables, including age level, gender, income range and
disease severity. METHODS: Participants enrolling in the
CarePatterns® Disease Management Program for Diabetes from
January 1, 2003 through June 30, 2003 and who opted to par-
ticipate in the free home-based HbA1c testing program were
included in the study. Allowing sufﬁcient time for test comple-
tion and return, Chi-squared (c2) and Cochran-Mantel-Hanzel
(CMH) statistics were utilized to examine the relationship
between home-testing participation and the independent 
